Medtronic for neurovascular and peripheral vascular medical devices.

• Aspiration-based Thrombectomy Systems: Devices like the Penumbra System and Indigo System used for mechanical thrombectomy to remove blood clots from neurovascular and peripheral vessels.
• Neurovascular Embolization Coiling Systems: Systems such as Penumbra Coil 400 designed to treat aneurysms and other neurovascular lesions.
• Neurovascular Access Systems: Devices like Neuron and BENCHMARK that provide intracranial access for various neurovascular therapies.
• Neurosurgical Aspiration Tools: The Artemis Neuro Evacuation Device for removing tissue and fluids in neurosurgery.
• Peripheral Embolization Devices: Detachable coils (e.g., Ruby Coil) and occlusion devices (e.g., POD) for blocking blood flow in peripheral vessels.
• Immersive Therapeutics: The Real Immersive System, which uses computer-based technologies to promote health, motor function, and cognition.

Penumbra (PEN) sells primarily to other companies rather than individuals. As a designer, developer, manufacturer, and marketer of specialized medical devices, its major customers are healthcare institutions such as hospitals, surgical centers, and specialized clinics (e.g., those performing neurovascular and peripheral interventions) that utilize its advanced medical technologies.

The provided company description indicates that Penumbra sells its products through direct sales organizations and distributors, who then supply these medical devices to the aforementioned healthcare providers. However, the background information does not list the names of specific customer companies or distributors.

Adam Elsesser, Chairman and Chief Executive Officer

Adam Elsesser co-founded Penumbra, Inc. in 2004 and has served as its Chief Executive Officer and a director since its inception, and as Chairman since January 2015. Before co-founding Penumbra, he led SMART Therapeutics, Inc., a medical device company focused on neuro-intervention, as its Chief Executive Officer from 2000 to 2002. Following SMART Therapeutics' acquisition by Boston Scientific Corporation, he served as President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Prior to his work in the medical device industry, Mr. Elsesser was a partner in the law firm of Shartsis Friese LLP.

Maggie Yuen, Chief Financial Officer

Maggie Yuen manages the financial strategy that supports Penumbra, Inc.'s aggressive research and development spending and market expansion. She is listed as the Chief Financial Officer on the company's leadership page.

Arani Bose, M.D., Co-Founder, Chief Innovator and Director

Dr. Arani Bose co-founded Penumbra, Inc. in 2004 and has been its Chief Innovator since 2004. He previously served as Chief Medical Officer and Chairman of Penumbra, Inc. from 2005 until 2015. Dr. Bose also founded Smart Therapeutics, Inc., where he developed neurovascular stents, and served as its Chairman. He was an Assistant Professor of Radiology and Neurology at the New York University School of Medicine.

Shruthi Narayan, President

Shruthi Narayan was promoted to President in September 2025, where she oversees the company's global operations and growth initiatives.

James F. Benenati, M.D., FSIR, Chief Medical Officer

Dr. James F. Benenati joined Penumbra, Inc. as Chief Medical Officer in September 2020. In this role, he contributes to clinical and medical affairs strategies and advises on global commercialization and market development activities. Prior to joining Penumbra, he practiced interventional radiology at the Miami Cardiac & Vascular Institute for over 30 years. He also served as the Director of the Fellowship Program and Medical Director of the Non-Invasive Vascular Laboratory at the institute.

Here are the key risks to Penumbra's business:

1. Regulatory and Product Liability Risks

As a medical device company, Penumbra operates in a highly regulated environment, subject to stringent domestic and international medical device regulations. Non-compliance, unforeseen issues with product safety or efficacy, or the need to meet evolving global regulatory standards (such as the EU MDR) can impede product approvals, hinder development and manufacturing activities, and result in costly product recalls or significant legal liabilities. The company has faced past allegations of product design defects, such as with its Jet 7 Xtra Flex catheter, which led to a voluntary recall and associated legal scrutiny, highlighting the tangible nature of this risk.

2. Intense Competition and Technological Obsolescence

Penumbra operates in a highly competitive medical device market characterized by rapid technological advancements and short product life cycles. The company faces significant competition from larger, well-capitalized players with extensive resources and established distribution networks, including companies like Boston Scientific, Medtronic, and Stryker. To maintain its market position and avoid technological obsolescence, Penumbra must continuously innovate and invest significantly in research and development. Failure to successfully develop and commercialize new products or to effectively compete against superior or more cost-effective technologies introduced by rivals could adversely affect its market share and financial performance.

3. Reimbursement Landscape Changes

The demand for Penumbra's medical devices is significantly influenced by the ability of healthcare providers to obtain adequate reimbursement for procedures utilizing these products. Reimbursement levels vary substantially across different countries and regions, originating from government-sponsored and private health insurance plans. Changes in healthcare policies, shifts in private insurance coverage decisions, or requirements for additional clinical data before or after recognizing coverage and reimbursement for Penumbra's products could negatively impact their adoption and sales.

Here are the addressable market sizes for Penumbra's main products and services:

• Neurovascular Thrombectomy Systems (for ischemic stroke):
  • The global neurothrombectomy devices market size was estimated at USD 825.92 million in 2025 and is predicted to reach approximately USD 1,494.32 million by 2034. North America accounted for 38.12% of the neurovascular thrombectomy devices market revenue in 2025.
  • Another source reported the global neurovascular thrombectomy devices market size at USD 3.00 billion in 2024, projected to reach USD 5.00 billion by 2032.
• Neurovascular Embolization Coiling Systems (for aneurysms and other neurovascular lesions):
  • The global neurovascular embolization market was valued at USD 1.4 billion in 2022 and is estimated to reach USD 2.5 billion by 2032. The U.S. neurovascular embolization market accounted for USD 503 million in 2022.
  • The global neuroendovascular coil market was estimated at USD 1.22 billion in 2024 and is expected to reach USD 1.98 billion by 2030. The USA neuroendovascular coil market reached USD 0.46 billion in 2024.
  • The global intracranial aneurysm market was valued at USD 1.74 billion in 2025 and is projected to grow to USD 2.95 billion by 2034. Endovascular coiling, a treatment type, accounted for 66.7% market share in 2025 for the intracranial aneurysm market and is expected to exceed USD 2.7 billion by 2035. The U.S. intracranial aneurysm market was USD 637.8 million in 2025.
• Peripheral Aspiration-Based Thrombectomy Systems and Peripheral Embolization Devices:
  • The global peripheral thrombectomy devices market size was valued at USD 684.99 million in 2025 and is expected to reach USD 1,134.50 million by 2033. The U.S. peripheral vascular thrombectomy devices market captured 42% of the revenue share in 2025 within North America.
  • The global peripheral embolization devices market size was valued at USD 11.50 billion in 2022 and is expected to reach USD 6.10 billion by 2030, growing at a CAGR of 11.50%. Another report states the peripheral embolization device market was valued at USD 696.45 million in 2025 and is expected to increase to USD 1,118.35 million by 2032. North America dominates this market.
• Immersive Computer-Based Technologies and Immersive Therapeutics (Real Immersive System):
  • The global digital therapeutics market size was estimated at USD 7.88 billion in 2024 and is expected to reach approximately USD 56.76 billion by 2034. North America contributed the largest market share of 44.03% in 2023.
  • The global immersive technologies market size was valued at USD 53.29 billion in 2025 and is projected to grow to USD 500.27 billion by 2034. Healthcare and life sciences represent nearly 14% of this market share.
  • The Global Immersive Technology in Healthcare Market is projected to grow from USD 4.21 billion in 2025 to USD 12.48 billion by 2031.

Expected Drivers of Future Revenue Growth for Penumbra (PEN)

Penumbra (PEN) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies and product advancements:

1. Expansion and Innovation in Computer Assisted Vacuum Thrombectomy (CAVT) Portfolio

   Penumbra expects significant growth from its expanding portfolio of Computer Assisted Vacuum Thrombectomy (CAVT) products. Recent and anticipated product launches, such as Lightning Bolt 16 and Lightning Flash 3.0, have received FDA clearance and are designed to enhance clot detection and removal. Furthermore, the Thunderbolt system, currently in the final stages of FDA review, is expected to stimulate the U.S. market, especially for stroke treatment. The company plans to launch multiple new CAVT products in the United States, targeting market share gains and growth across deep vein thrombosis, pulmonary embolism, and arterial applications.

2. International Market Expansion

   The company is strategically focused on materially increasing its international revenues and profitability over the next three years. This includes expanding its presence, particularly in Europe, by introducing advanced thrombectomy products, including its first-generation computer-aided devices, to global teams. Penumbra anticipates double-digit growth in its international business, with expected alleviation of China-specific headwinds by early next year.

3. Growing Adoption of U.S. Thrombectomy and Embolization Products

   Penumbra foresees continued strong demand and increased market penetration for its thrombectomy and embolization products in the U.S. This growth is being fueled by robust demand for its U.S. VTE (Venous Thromboembolism) franchise and embolization solutions. Strategic investments, such as the dedicated expansion of the U.S. Peripheral Embolization sales team and the successful launch of products like Ruby XL, have already resulted in significant sequential growth in embolization revenue.

4. Positive Clinical Data Driving Product Adoption

   The outcomes from landmark clinical trials, such as the STORM-PE randomized controlled trial, are crucial for accelerating product adoption. The STORM-PE results demonstrated that CAVT, combined with anticoagulation, significantly improved functional outcomes for patients with pulmonary embolism. These findings are expected to build physician confidence and lead to a more rapid integration of Penumbra's advanced thrombectomy systems into hospital protocols.

Share Repurchases

• Penumbra's Board of Directors authorized a share repurchase program of up to $200 million on August 5, 2024, set to expire on July 31, 2025.
• As part of this authorization, Penumbra entered into an accelerated share repurchase agreement (ASR) on August 12, 2024, to repurchase $100 million of its common stock.
• An initial delivery of approximately 474,000 shares of Penumbra's common stock was received on August 13, 2024, with the final settlement of the ASR expected in the third quarter of 2024.

Inbound Investments

• Boston Scientific Corporation announced in January 2026 its definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion to $15 billion in a cash and stock deal.

Capital Expenditures

• Penumbra's capital expenditures were approximately $19.46 million for the last 12 months as of December 31, 2024.
• Annual capital expenditures were $13 million in 2023, $14 million in 2024, and $5.47 million in 2025.
• Strategic capital investments have been directed towards establishing facilities, such as the Costa Rica facility, to support global market expansion.